Steroid receptor coactivator 3-deficient regulatory T cells eradicate multiple solid tumors in syngeneic mouse models - PubMed
8 hours ago
- #immunotherapy
- #regulatory T cells
- #cancer treatment
- SRC-3 is highly expressed in regulatory T cells (Tregs) and crucial for their immunosuppressive activity.
- Disrupting SRC-3 in Tregs eliminates triple-negative breast cancer (TNBC) and prostate cancer in syngeneic mouse models without causing immune-related adverse events (irAEs).
- SRC-3 knockout (KO) Tregs infiltrate tumors and promote the infiltration of CD8+, CD4+, and NK immune cells into the tumor microenvironment (TME).
- SRC-3KO Tregs also eradicate glioblastoma, melanoma, and lung cancer in syngeneic mouse models by creating an anti-tumor immune environment.
- The findings support the development of SRC-3-targeted Treg modulation as a safe and effective immunotherapy for treatment-resistant cancers.